Fig. 10.
(A–B) Immunoblot analysis for Bcl-xL expression and PARP cleavage in CUR or F127250-CUR (nano-CUR) cancer cells. Note: F127250-CUR (nano-CUR) has shown a decrease in Bcl-xL expression compared to free curcumin (CUR) which indicates reduced cell survival. F127250-CUR has also shown enhanced PARP cleavage compared to free CUR. DMSO and NPs (F127250, magnetic nanoparticles contain β-cyclodextrin and pluronic polymer F127 coatings) control did not show any effects. (C) Ultrastructural cellular changes induced by CUR or F127250-CUR treatments.